Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the
leading causes of death and disability worldwide. As such, new therapeutic interventions are …

Ischaemic heart disease and the heart failure that often results, remain the leading causes of
death and disability in Europe and worldwide. As such, in order to prevent heart failure and …

Acute myocardial infarction (AMI) and the heart failure that often follows, are major causes of
death and disability worldwide. As such, new therapies are required to limit myocardial …

Rationale: Despite 4 decades of intense effort and substantial financial investment, the
cardioprotection field has failed to deliver a single drug that effectively reduces myocardial …

Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide.
As a result, novel therapies are still needed to protect the heart from the detrimental effects of …

Rationale: Allogeneic bone marrow–derived mesenchymal stem cells (MSCs) and
cardiosphere-derived cells (CDCs) have each entered clinical trials, but a direct comparison …

The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly
owing to underlying endothelial dysfunction in both diseases. Millions of patients with …

Rationale: Metformin has been demonstrated to decrease infarct size (IS) and prevent
postinfarction left ventricular (LV) remodeling in rodents when given intravenously at the …

The international consortium TACTICS (Transnational Alliance for Regenerative Therapies
in Cardiovascular Syndromes) has recently addressed key priorities in the field of cell-based …

Abstract Background The phosphodiesterase-5 (PDE5) inhibitors that have been available
for nearly 20 years are highly effective in treating erectile dysfunction and have been …